Orforglipron vs 5-Amino-1MQ
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
OrforglipronFat Loss & Metabolic
5-Amino-1MQ- Summary
- Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
- 5-Amino-1MQ is a small-molecule NNMT (Nicotinamide N-methyltransferase) inhibitor that raises intracellular NAD+ levels and promotes fat burning. It is notable for targeting adipose tissue directly, reducing fat cell size and number while increasing metabolic rate.
- Half-Life
- ~12 hours (once-daily oral dosing)
- Estimated 4–8 hours
- Admin Route
- Oral
- Oral
- Research
- —
- —
- Typical Dose
- 12 mg → 24 mg → 36 mg → 45 mg
- 50–100 mg
- Frequency
- Once daily
- Once to twice daily
- Key Benefits
- Oral pill — no injections required
- Once-daily dosing without food restrictions (unlike oral semaglutide)
- Up to 9.4% body weight reduction in Phase 2 at 36 weeks
- Significant HbA1c reduction in type 2 diabetes trials
- Small-molecule stability — no cold chain requirements
- Broadens access for injection-averse patients
- Potential class-defining convenience advantage over injectable GLP-1s
- Raises intracellular NAD+ levels
- Directly targets adipose tissue for fat reduction
- Reduces fat cell size and differentiation
- Increases basal metabolic rate
- SIRT1 activation for metabolic regulation
- No stimulant cardiovascular side effects
- Synergistic with intermittent fasting and caloric restriction
- May have anti-aging metabolic benefits
- Side Effects
- Nausea (most common, dose-dependent)
- Vomiting
- Diarrhea
- Decreased appetite
- +2 more
- Generally well-tolerated in available studies
- Mild GI discomfort (rare)
- Limited long-term human data
- Stacks With
- —
- —